Ghrelin Receptor Agonist Shows Promise for Muscle and Bone Health in Older Adults

This completed clinical trial examined whether anamorelin hydrochloride, a ghrelin receptor agonist, could improve muscle and bone health in adults suffering from both sarcopenia and osteopenia. The study addressed a critical health challenge: adults with low muscle mass typically also have compromised bone density, creating a dangerous combination that increases vulnerability to falls, fractures, and other serious injuries.

The randomized, placebo-controlled trial enrolled 32 participants and ran from December 2019 to January 2023. Participants received either anamorelin hydrochloride or placebo while researchers measured various indicators of muscle and bone health. Ghrelin is a hormone naturally produced in the stomach that stimulates appetite and promotes growth hormone release, making its receptor an attractive therapeutic target.

The dual decline of muscle and bone mass represents a significant threat to healthy aging and independence. Traditional approaches often address these conditions separately, but this trial explored whether a single intervention targeting the ghrelin pathway could benefit both systems simultaneously.

While specific results have not been fully disclosed, this study was designed as a proof-of-concept trial to inform the design of larger, definitive studies. The research represents an important step toward developing hormone-based therapies for age-related muscle and bone loss.

The implications for longevity and healthspan are significant. If ghrelin receptor agonists prove effective, they could offer a novel approach to maintaining physical function and reducing fracture risk in aging populations, potentially extending years of independent living.